These results in p53-wildtype cells are consistent with a previous study of a ruthenium complex containing a bis-benzimidazole derivative, which showed radiosensitising ability and G2/M cell cycle arrest in p53-wildtype A375 melanoma cells39, 40. This evidence concerns the gene TP53 and melanoma.